Intralymphatic Immunotherapy in Increasing Doses, After Subcutaneous Immunotherapy

Inclusion Criteria: * Age 18-55 * Accepted and signed informed consent. * Recently (within 20 months) ended a full 3 year program with subcutaneous immunotherapy (SCIT) with amelioration of symptoms but not full symptom relief. Exclusion Criteria: * Previously subcutaneous immunotherapy (SCIT) with total symptom relief. * Previously SCIT but no symptom improvement at all. * Sensitizations to house dust mite or furry animals, with symptoms. * Severe atopic dermatitis. * Patients with significant diseases other than allergic rhinitis. A significant disease is defined as a disease which in the opinion of the investigator may either put the patient at risk because of participation in the study or a disease which may influence the results of the study or the patient's ability to participate in the study. * Patients with a respiratory tract infection in the past 4 weeks prior to Visit 2. * Pregnant or nursing women or women of childbearing potential not using a medically approved means of contraception (i.e., oral contraceptives, intrauterine devices, diaphragm, or subdermal implants). * Known autoimmune or collagen disease * Cardiovascular disease * Perennial pulmonary disease including asthma * Hepatic disease * Known renal insufficiency * Cancer * Hematologic disease * Chronic infectious disease * Any medication with a possible side-effect of interfering with the immune response * Previous immuno- or chemotherapy, apart from SCIT * Disease or conditions rendering the treatment of anaphylactic reactions difficult (symptomatic coronary heart diseases, severe arterial hypertension and treatment with β-blockers) * Major metabolic disease * Known or suspected allergy to the study product * Obesity with BMI \> 30 since subcutaneous fat makes ultrasound imaging of lymph nodes harder which may risk the correct placement of injection. * Patients who, in the opinion of the investigator, abuse alcohol or drugs within 2 years prior to Visit 1. * Patients who have taken an investigational drug within 1 month or six half lives, whichever is greater, prior to Visit 1. * Mental incapability of coping with the study * Withdrawal of informed consent